Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EPS (Basic)EPS (Weighted Average and Diluted)Interest & Investment IncomeInterest ExpensesInterest ExpensesNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nautilus Biotechnology (NAUT) EBITDA (2020 - 2025)

Nautilus Biotechnology has reported EBITDA over the past 6 years, most recently at -$16.5 million for Q1 2025.

  • Quarterly results put EBITDA at -$16.5 million for Q1 2025, up 14.25% from a year ago — trailing twelve months through Mar 2025 was -$68.5 million (down 1.94% YoY), and the annual figure for FY2021 was -$50.5 million, down 223.25%.
  • EBITDA reached -$16.5 million in Q1 2025 per NAUT's latest filing, up from -$19.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$8.4 million in Q1 2021 and bottomed at -$19.2 million in Q1 2024.
  • Median EBITDA over the past 5 years was -$15.5 million (2023), compared with a mean of -$15.0 million.
  • The largest annual shift saw EBITDA tumbled 264.58% in 2021 before it increased 14.25% in 2025.
  • Over 5 years, EBITDA stood at -$16.9 million in 2021, then grew by 10.01% to -$15.2 million in 2022, then decreased by 2.28% to -$15.5 million in 2023, then dropped by 23.82% to -$19.2 million in 2024, then increased by 14.25% to -$16.5 million in 2025.
  • Business Quant data shows EBITDA for NAUT at -$16.5 million in Q1 2025, -$19.2 million in Q1 2024, and -$15.5 million in Q3 2023.